title: Could edaravone prevent gentamicin ototoxicity? An experimental study.
abstract: OBJECTIVE
  Clinical application of gentamicin may cause nephrotoxicity and ototoxicity. Our study is the first study to investigate the protective effects of edaravone against the gentamicin-induced ototoxicity. We investigated the protective effect of intraperitoneal (i.p.) edaravone application against gentamicin-induced ototoxicity in guinea pigs.
  
  
  METHODS
  Fourteen guinea pigs were divided into two equal groups consisting of a control group and a study group. One-hundred sixty milligrams per kilogram subcutaneous gentamicin and 0.3 mL i.p. saline were applied simultaneously once daily to seven guinea pigs in the control group (group 1). One-hundred sixty milligrams per kilogram gentamicin was applied subcutaneously and 3 mg/kg edaravone was applied intraperitoneally once daily for 7 days simultaneously to seven guinea pigs in the study group (group 2). Following the drug application, auditory brainstem response measurements were performed for the left ear on the 3rd and 7th days.
  
  
  RESULTS
  Hearing threshold values of the group 1 and group 2 measured in the 3rd day of the study were detected as 57.14 ± 4.88 and 82.86 ± 7.56, respectively. This difference was statistically significant ( p < 0.05). Hearing threshold values of the group 1 and group 2 measured in the 7th day of the study were detected as 87.14 ± 4.88 and 62.86 ± 4.88, respectively. This difference was statistically significant ( p < 0.05).
  
  
  CONCLUSIONS
  A statistically significant difference between the average threshold values of edaravone-administered group 2 and that of group 1 without edaravone was found. These differences show that systemic edaravone administration could diminish ototoxic effects of gentamicin and the severity of the hearing loss.
authors.affiliation: 1 Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Yüzüncü Yıl University, Van, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Turan
authors.affiliation: 2 Department of Otolaryngology-Head and Neck Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Ciğer
authors.affiliation: 2 Department of Otolaryngology-Head and Neck Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Arslanoğlu
authors.affiliation: 3 Department of General Surgery, Faculty of Medicine, Bozok University, Yozgat, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Börekci
authors.affiliation: 2 Department of Otolaryngology-Head and Neck Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir, Turkey.
authors.forename: K
authors.initials: K
authors.lastname: Önal
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005839:Gentamicins / Q000633:toxicity*; D006168:Guinea Pigs; D006309:Hearing / Q000187:drug effects*; D008297:Male
chemical_list: D016166:Free Radical Scavengers; D005839:Gentamicins; D000077553:Edaravone; D000983:Antipyrine
keywords: Gentamicin; edaravone; hearing loss; ototoxicity